AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03010046
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose intravenous infusion
Trial: NCT03010046
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline intravenous infusion
Trial: NCT00684008
Drug: CYT107 - Recombinant glycosylated human interleukin 7.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
Trial: NCT00565084
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 800 mg ibuprofen in one of the three treatment periods.
Trial: NCT00565084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo to ibuprofen in two of the three treatment periods.
Trial: NCT00275912
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00727246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo for 6 weeks
Trial: NCT04594213
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Trial: NCT04594213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Trial: NCT05812872
Drug: Toothgraft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particulate dentin
Trial: NCT05812872
Drug: Allograft
RxNorm normalized name: Ascent Human Amniotic Allograft 15mg Tissue Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralized corticocancellous allograft
Trial: NCT05812872
Drug: Alloplast
RxNorm normalized name: PASTE,COLOPLAST #2650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta tri-calcuim phosphate
Trial: NCT03586427
Drug: AGN-241751
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-241751 administered orally as a single tablet
Trial: NCT03586427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally as a single tablet
Trial: NCT02906527
Drug: Non-exposed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exposed group / Patients receiving VKA
Trial: NCT02906527
Drug: Exposed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposed group / Patients receiving DOAC
Trial: NCT01857817
Drug: VT-122
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
Trial: NCT01193478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral, once daily for 3 days
Trial: NCT01857817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules will be prepared to match the active drug.
Trial: NCT02392624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to omalizumab administered SC Q4W.
Trial: NCT03036202
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
Trial: NCT00193661
Drug: Testosterone Gel (1%)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03763877
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT02528981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04359316
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
Trial: NCT02538224
Drug: 2.5%ketoprofen gel + 3 % doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs
Trial: NCT02538224
Drug: :2.5%ketoprofen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
Trial: NCT00072319
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01106690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
Trial: NCT02346721
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg tablet administered orally once daily
Trial: NCT03646552
Drug: THX-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days.
Trial: NCT02641782
Drug: IL-2 i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
Trial: NCT02641782
Drug: IL-2 s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
Trial: NCT03408392
Drug: Test formulation A
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
Trial: NCT03408392
Drug: Reference formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
Trial: NCT02097264
Drug: NNC0109-0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
Trial: NCT02097264
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Trial: NCT01749215
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01526577
Drug: LC23-1306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
Trial: NCT01526577
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC23-1306 placebo
Trial: NCT03677557
Drug: 16,5% Cutaquig
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
Trial: NCT00346697
Drug: Omega-3 fatty acid administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOVAZA 1 gram capsules, 4 capsules daily
Trial: NCT00346697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn-oil placebo
Trial: NCT00326859
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04287790
Drug: Acamprosate, naltrexone, or disulfiram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
Trial: NCT03599089
Drug: CA-008
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose wound infiltration prior to surgical incision closure
Trial: NCT03599089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose wound infiltration prior to surgical incision closure
Trial: NCT03599089
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg IV administered intraoperatively
Trial: NCT03599089
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV administered intraoperatively
Trial: NCT01760252
Drug: Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
Trial: NCT00462501
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00462501
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02784899
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.
Trial: NCT04454918
Drug: [14C]-TAK-906 Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-TAK-906 intravenous infusion.
Trial: NCT04454918
Drug: [14C]-TAK-906 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-TAK-906 oral solution.
Trial: NCT03551561
Drug: CSAC
RxNorm normalized name: Calcium Sucrose Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
Trial: NCT02314819
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Trial: NCT00973804
Drug: EPOCH-F/R
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00973804
Drug: Transplant Preparative Regimen (Flu/Cy/Mes)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02504151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01177371
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01177371
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04616456
Drug: [F-18]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT01774396
Drug: Emervel® Touch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emervel® Touch will be injected only in the intervention group.
Trial: NCT01702649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day.
Trial: NCT02034227
Drug: SG2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
Trial: NCT02995239
Drug: CJ-12420 formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJ-12420 formulation 2
Trial: NCT03739203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied in capsules
Trial: NCT03739203
Drug: Antidepressant Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT as prescribed by the physician per standard of care in clinical practice.
Trial: NCT01935206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729559
Drug: 5000 Units unfractionated Heparin Q 8 hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous thromboembolic prophylaxis medication
Trial: NCT01077076
Drug: Prilosec OTC™ Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilosec OTC™ Tablets taken once daily for 11 days.
Trial: NCT00561509
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use within normal clinical practice
Trial: NCT04148846
Drug: Dypirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
Trial: NCT02116309
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04148846
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
Trial: NCT04148846
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally
Trial: NCT03292731
Drug: Safety study of 500 mg dose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to 250 mg or 500 mg dose
Trial: NCT03478982
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose for inhalation
Trial: NCT00171561
Drug: valsartan/hydrochlorothiazide
RxNorm normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03773276
Drug: Norepinephrine boluses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.
Trial: NCT01721044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01721044
Drug: cDMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to take background cDMARD therapy throughout study.
Trial: NCT01499355
Drug: oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Trial: NCT00003469
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT02668653
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02668653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01017198
Drug: BIIB0121 and Antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessing the effect of antacid use on BIIB021
Trial: NCT02639221
Drug: PXT002331
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02565108
Drug: GWP42003-P 20 mg/kg/Day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Trial: NCT02565108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Trial: NCT02535806
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal dose For CNS negative patients, Day 1 and Day 8
Trial: NCT02535806
Drug: Methotrexate / Hydrocortisone / Cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
Trial: NCT02936596
Drug: Ursodeoxycholic acid combination of immunosuppressive agents
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
Trial: NCT00433368
Drug: L-Ornithine L-Aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01005810
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules twice daily for 8 weeks
Trial: NCT02708186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral, matching tablets
Trial: NCT00068419
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02282514
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Trial: NCT01804127
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
Trial: NCT00848965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01510704
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01510704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01237197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
Trial: NCT04388254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral tablets
Trial: NCT00404612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO BID
Trial: NCT03358407
Drug: GSK2983559
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
Trial: NCT03358407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.
Trial: NCT04624295
Drug: Non-Early aspirin Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Trial: NCT01017302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutenaous once weekly for 4 weeks
Trial: NCT01017302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose in week 5